Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps

Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps

Spinal muscular atrophy (SMA) is a recessive disorder caused by a mutation in the survival motor neuron 1 gene (SMN1); it affects 1 in 11 000 newborn infants. The most severe and most common form, type 1 SMA, is associated with early mortality in most cases and severe disability in survivors. Nusine...

Descripció completa

Dades bibliogràfiques
Autors principals:	Gidaro, T, Servais, L
Format:	Journal article
Idioma:	English
Publicat:	Wiley 2018

Ítems similars

Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen
per: Aragon-Gawinska, K, et al.
Publicat: (2019)

Nusinersen and spinal muscular atrophies: Where are we in 2020?
per: Satish V Khadilkar, et al.
Publicat: (2020-01-01)

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
per: Finkel, RS, et al.
Publicat: (2017)

Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
per: Tommaso Nuzzo, et al.
Publicat: (2023-02-01)

Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
per: Benjamin Stolte, et al.
Publicat: (2018-10-01)

Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
per: Maren Freigang, et al.
Publicat: (2021-07-01)

Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study
per: Aragon-Gawinska, K, et al.
Publicat: (2018)

Nusinersen versus sham control in later-onset spinal muscular atrophy
per: Mercuri, E, et al.
Publicat: (2018)

Profiling neuroinflammatory markers and response to nusinersen in paediatric spinal muscular atrophy
per: Qiang Zhang, et al.
Publicat: (2024-10-01)

History of development of the life-saving drug “Nusinersen” in spinal muscular atrophy
per: Jiaying Qiu, et al.
Publicat: (2022-08-01)

Physical Therapy and Nusinersen Impact on Spinal Muscular Atrophy Rehabilitative Outcome
per: Andrada Mirea, et al.
Publicat: (2022-06-01)

Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
per: Maria Carmela Pera, et al.
Publicat: (2021-08-01)

Nusinersen in spinal muscular atrophy: Respiratory outcomes at tertiary care centers
per: Fahad Alsohime, et al.
Publicat: (2020-01-01)

Common complications in spinal muscular atrophy (SMA) type 1 after nusinersen treatment
per: Yiğithan Güzin, et al.
Publicat: (2024-11-01)

Analysis of the efficacy and adverse effects of nusinersen in the treatment of children with spinal muscular atrophy in China
per: Dan Li, et al.
Publicat: (2024-07-01)

Quality of Life Assessment in Romanian Patients with Spinal Muscular Atrophy Undergoing Nusinersen Treatment
per: Bogdana Cavaloiu, et al.
Publicat: (2024-08-01)

Treatment with nusinersen in a girl with spinal muscular atrophy type 1 - Case report
per: Tanja Loboda, et al.
Publicat: (2020-07-01)

Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy
per: Isabell Cordts, et al.
Publicat: (2020-01-01)

New treatments in spinal muscular atrophy: an overview of currently available data
per: Ramdas, S, et al.
Publicat: (2020)

Safety and Efficacy of Nusinersen Focusing on Renal and Hematological Parameters in Spinal Muscular Atrophy
per: Hüseyin Bahadır Şenol, et al.
Publicat: (2025-01-01)

Nusinersen Wearing-Off in Adult 5q-Spinal Muscular Atrophy Patients
per: Alma Osmanovic, et al.
Publicat: (2021-03-01)

Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy
per: Francesco Errico, et al.
Publicat: (2022-10-01)

Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
per: Praveen Thokala, et al.
Publicat: (2020-10-01)

Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy
per: Bakri Elsheikh, et al.
Publicat: (2021-04-01)

Exploring the Influence of Concurrent Nutritional Therapy on Children with Spinal Muscular Atrophy Receiving Nusinersen Treatment
per: Eymen Pinar, et al.
Publicat: (2024-07-01)

Nusinersen Treatment for Spinal Muscular Atrophy: Retrospective Multicenter Study of Pediatric and Adult Patients in Kuwait
per: Asma AlTawari, et al.
Publicat: (2024-06-01)

Clinical and Electrophysiological Changes in Pediatric Spinal Muscular Atrophy after 2 Years of Nusinersen Treatment
per: Mihaela Axente, et al.
Publicat: (2022-09-01)

Intrathecal administration of nusinersen for spinal muscular atrophy: report of three cases with severe spinal deformity
per: Sayo Nakao, et al.
Publicat: (2020-04-01)

Real-world analysis of the efficacy and safety of nusinersen in pediatric patients with spinal muscular atrophy
per: Wenjing Li, et al.
Publicat: (2025-02-01)

Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysis
per: Tim Hagenacker, et al.
Publicat: (2024-09-01)

Unveiling the adverse events of Nusinersen in spinal muscular atrophy management based on FAERS database
per: Ying Jiang, et al.
Publicat: (2024-07-01)

Safety analysis of laboratory parameters in paediatric patients with spinal muscular atrophy treated with nusinersen
per: Xiaomei Zhu, et al.
Publicat: (2024-07-01)

Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen
per: Tristan Weaver, et al.
Publicat: (2021-09-01)

Effects of nusinersen on motor function in children with spinal muscular atrophy: a retrospective study
per: Yuyi Chen, et al.
Publicat: (2024-07-01)

Quality of Life Outcomes According to Differential Nusinersen Exposure in Pediatric Spinal Muscular Atrophy
per: Meaghann S. Weaver, et al.
Publicat: (2021-07-01)

Nusinersen injections in adults and children with spinal muscular atrophy: a single-center experience
per: Can Özütemiz, et al.
Publicat: (2020-11-01)

Nusinersen efficacy data for 24‐month in type 2 and 3 spinal muscular atrophy
per: Marika Pane, et al.
Publicat: (2022-03-01)

Experience of Nusinersen in children with proximal spinal muscular atrophy 5q in Moscow region
per: M. V. Panteleeva
Publicat: (2022-12-01)

Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives
per: Dangouloff T, et al.
Publicat: (2019-10-01)

A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
per: Konstantinos Biliouris, et al.
Publicat: (2018-09-01)